Livforsakringsbolaget Skandia, Omsesidigt Catalyst Pharmaceuticals, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.72 Billion
- Q3 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 110,900 shares of CPRX stock, worth $2.36 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
110,900
Previous 74,900
48.06%
Holding current value
$2.36 Million
Previous $1.16 Million
90.0%
% of portfolio
0.13%
Previous 0.09%
Shares
5 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$398 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$171 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$133 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$121 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$64.2 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.19B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...